Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Cross-protection is crucial for prophylactic HPV vaccination.

Lehtinen M.

Lancet Infect Dis. 2012 Oct;12(10):742-3. doi: 10.1016/S1473-3099(12)70203-7. Epub 2012 Aug 22. No abstract available.

PMID:
22920952
2.

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis.

Malagón T, Drolet M, Boily MC, Franco EL, Jit M, Brisson J, Brisson M.

Lancet Infect Dis. 2012 Oct;12(10):781-9. doi: 10.1016/S1473-3099(12)70187-1. Epub 2012 Aug 22. Review.

PMID:
22920953
3.

Cost-effectiveness of the prophylactic HPV vaccine: an application to the Netherlands taking non-cervical cancers and cross-protection into account.

Luttjeboer J, Westra TA, Wilschut JC, Nijman HW, Daemen T, Postma MJ.

Vaccine. 2013 Aug 20;31(37):3922-7. doi: 10.1016/j.vaccine.2013.06.044. Epub 2013 Jun 24.

PMID:
23806241
4.

Postlicensure monitoring of HPV vaccination programmes.

Markowitz LE, Hariri S.

Lancet Infect Dis. 2014 Oct;14(10):904-5. doi: 10.1016/S1473-3099(14)70871-0. Epub 2014 Aug 5. No abstract available.

PMID:
25107681
5.

HPV vaccination and cervical cancer.

Szarewski A.

Curr Oncol Rep. 2012 Dec;14(6):559-67. doi: 10.1007/s11912-012-0259-3.

PMID:
22890794
6.
7.

Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types.

Szarewski A.

Expert Rev Vaccines. 2012 Jun;11(6):645-57. doi: 10.1586/erv.12.42.

PMID:
22873123
8.

A randomized, observer-blinded immunogenicity trial of Cervarix(®) and Gardasil(®) Human Papillomavirus vaccines in 12-15 year old girls.

Draper E, Bissett SL, Howell-Jones R, Waight P, Soldan K, Jit M, Andrews N, Miller E, Beddows S.

PLoS One. 2013 May 1;8(5):e61825. doi: 10.1371/journal.pone.0061825. Print 2013.

9.

Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types.

Herrero R.

J Infect Dis. 2009 Apr 1;199(7):919-22. doi: 10.1086/597308. No abstract available.

10.

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years.

Einstein MH, Baron M, Levin MJ, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini SL, Schuind A, Datta SK, Descamps D; HPV-010 Study Group.

Hum Vaccin. 2011 Dec;7(12):1359-73. doi: 10.4161/hv.7.12.18282. Epub 2011 Dec 1.

11.

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

Stanley M, Gissmann L, Nardelli-Haefliger D.

Vaccine. 2008 Aug 19;26 Suppl 10:K62-7. doi: 10.1016/j.vaccine.2008.05.066. Review.

PMID:
18847558
12.

Measuring serum antibody to human papillomavirus following infection or vaccination.

Frazer IH.

Gynecol Oncol. 2010 Jun;118(1 Suppl):S8-11. doi: 10.1016/j.ygyno.2010.04.003. Review.

PMID:
20494221
13.

[Developments in HPV vaccination].

de Melker H, Kenter G, van Rossum T, Conyn-van Spaendonck M.

Ned Tijdschr Geneeskd. 2012;156(47):A5410. Review. Dutch.

PMID:
23171565
14.

Cross protection against HPV might prevent type replacement.

Verdenius I, Groner JA, Harper DM.

Lancet Infect Dis. 2013 Mar;13(3):195. doi: 10.1016/S1473-3099(13)70024-0. No abstract available.

PMID:
23427887
15.

Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.

Jagu S, Karanam B, Gambhira R, Chivukula SV, Chaganti RJ, Lowy DR, Schiller JT, Roden RB.

J Natl Cancer Inst. 2009 Jun 3;101(11):782-92. doi: 10.1093/jnci/djp106. Epub 2009 May 26.

16.

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Coupé VM, Bogaards JA, Meijer CJ, Berkhof J.

Vaccine. 2012 Feb 27;30(10):1813-22. doi: 10.1016/j.vaccine.2012.01.001. Epub 2012 Jan 10.

PMID:
22240341
17.
18.

Prophylactic HPV vaccination for the prevention of cervical cancer.

Hernandez BY.

Hawaii Med J. 2007 Jul;66(7):190-1. No abstract available.

PMID:
17879858
19.

Human papillomavirus: current status and issues of vaccination.

Malik H, Khan FH, Ahsan H.

Arch Virol. 2014 Feb;159(2):199-205. Review.

PMID:
24022639
20.

HPV vaccination: the beginning of the end of cervical cancer? - A Review.

Lepique AP, Rabachini T, Villa LL.

Mem Inst Oswaldo Cruz. 2009 Feb;104(1):1-10. Review.

Items per page

Supplemental Content

Write to the Help Desk